Anaptysbio (ANAB) Cash & Current Investments (2016 - 2026)

Anaptysbio has reported Cash & Current Investments for 11 years, with the latest figure at $286.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 15.73% year-over-year to $286.5 million; the trailing twelve-month figure through Mar 2026 stood at $286.5 million (down 15.73% YoY), and the FY2025 full-year result was $311.6 million, down 19.13% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $286.5 million, down from $311.6 million in the prior quarter.
• The five-year high for Cash & Current Investments was $505.6 million in Q1 2022, with the low at $249.0 million in Q3 2025.
• Historically, Cash & Current Investments has averaged $380.6 million across 5 years, with a median of $390.9 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 33.05% — and 2025, when it slumped 42.12%.
• Anaptysbio's Cash & Current Investments stood at $441.2 million in 2022, then dropped by 11.41% to $390.9 million in 2023, then slipped by 1.41% to $385.4 million in 2024, then fell by 19.13% to $311.6 million in 2025, then decreased by 8.08% to $286.5 million in 2026.
• The last three Cash & Current Investments figures came in at $286.5 million (Q1 2026), $311.6 million (Q4 2025), and $249.0 million (Q3 2025), per Business Quant data.